4,000
Participants
Start Date
September 30, 2015
Primary Completion Date
July 31, 2017
Study Completion Date
July 31, 2017
dihydroartemisinin-piperaquine (DHAp)
In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
reactive case detection
Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
Swaziland Ministry of Health, Mbabane
Ministry of Health, Swaziland
OTHER_GOV
Clinton Health Access Initiative, Eswatini
UNKNOWN
University of Texas
OTHER
University of California, San Francisco
OTHER